<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181764</url>
  </required_header>
  <id_info>
    <org_study_id>KRN23-001</org_study_id>
    <nct_id>NCT02181764</nct_id>
  </id_info>
  <brief_title>A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia</brief_title>
  <official_title>A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and tolerability of KRN23 after a single
      subcutaneous (SC) administration in subjects with X-linked hypophosphatemic
      rickets/osteomalacia (XLH) in Japan or Korea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and types of adverse events</measure>
    <time_frame>Up to 7 weeks after dosing</time_frame>
    <description>The safety of KRN23 assessed by number and types of adverse events, laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profiles of pharmacokinetics</measure>
    <time_frame>Pre-dose, 24, 48, 96, 168, 336, 504, 672, 840, 1176 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>X-linked Hypophosphatemic Rickets/Osteomalacia</condition>
  <arm_group>
    <arm_group_label>KRN23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC administration on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRN23</intervention_name>
    <description>Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg</description>
    <arm_group_label>KRN23</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years or older

          2. Patients with XLH

        Exclusion Criteria:

          1. Have an active infection or chronic inflammatory disease

          2. Have uncontrolled hypertension

          3. Have uncontrolled diabetes mellitus

          4. History of known immunodeficiency

          5. Use of a pharmacologic vitamin D metabolite or its analogs within 21 days prior to
             screening and after screening

          6. Use of phosphate, calcium preparation, calcimimetics, aluminum hydroxide antacids,
             thiazide diuretic, acetazolamide, or phosphate, calcium, and/or vitamin D-containing
             supplements within 10 days prior to screening and after screening

          7. Pregnant or lactating females, women who are possibly pregnant or patients who have no
             intention of utilizing adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2014</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XLH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Osteomalacia</mesh_term>
    <mesh_term>Rickets, Hypophosphatemic</mesh_term>
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

